5 patents currently held
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Apr 2029. from the record
Of the 10 now held by other companies, 9 name Neurmedix Inc. as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
2
Ending by 2030
Apr 2029
Next term end
4
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2029 · High confidence
Also notable
Ends Jun 2036 · High confidence
Also notable
Ends Apr 2041 · High confidence
Crystalline Anhydrate Forms Of A Pharmaceutical
US 9,555,046
The largest patent family in this portfolio, 9 related applications, renewed at every maintenance window due so far. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Treatment of Ascites
US 11,364,277
A family of 6 related applications built on the 2022 grant. Protection runs to 2036.
Formulations of Terlipressin
US 12,156,898
Granted 2024. Too new for citation comparison; protection runs to 2041.
Formerly held, still cited
Notable
Ends Jul 2031 · High confidence
Renewed at every maintenance window since the 2013 grant; no more fees are due before its term ends in 2031.
now held by Neurmedix, Inc.
Also notable
Ends Sep 2031 · High confidence
The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2031.
now held by Neurmedix, Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Crystalline Anhydrate Forms Of A Pharmaceutical | 2 in force | to Apr 2029 |
| Methods of Treating Disease with Terlipressin | 1 in force | to Feb 2043 |
| Formulations of Terlipressin | 1 in force | to Apr 2041 |
| Treatment of Ascites | 1 in force | to Jun 2036 |
Patents held now
Soonest term end first.
Showing 1 to 5 of 5
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,555,046 | Crystalline Anhydrate Forms Of A Pharmaceutical In force · High confidence | In force | High confidence | |
| US 12,774,300 | Crystalline Solvate Forms of a Pharmaceutical In force · High confidence | In force | High confidence | |
| US 11,364,277 | Treatment of Ascites In force · High confidence | In force | High confidence | |
| US 12,156,898 | Formulations of Terlipressin In force · High confidence | In force | High confidence | |
| US 12,685,756 | Methods of Treating Disease with Terlipressin In force · High confidence | In force | High confidence |
Also on record, not counted in the 5: 10 patents in force now held by others · 32 patents ended · 7 applications pending · 53 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.